Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
A new study has found that taking a regular steroid inhaler can reduce the risk of severe symptoms of COVID-19.
The research, published in the Lancet, aimed to understand whether existing lung conditions make people more severely ill with COVID-19 and whether medication for these conditions has an impact.
The researchers collected information from 75,463 people admitted to hospital with COVID-19 in the UK between 17 January 2020 and 3 August 2020. They looked at whether the person had asthma, chronic pulmonary disease, or both. They also collected information on their age, the medication they were taking, what treatment they received for COVID-19 and whether they died.
The results found that underlying lung conditions were common in people admitted to hospital for COVID-19. Specifically, the authors found that:
As we learn more about COVID-19, it is crucial to understand why some people become more ill and require hospital treatment, compared to others. This study helps us understand how underlying lung conditions could affect the course of the infection. A key finding shows that regular use of steroid inhalers could help to reduce the risk of death for older people with asthma.
Title: Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00013-8/fulltext
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
No description
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.